Parabasal cells

1. Dehydroepiandrosterone decreases parabasal cells in humans (-27.7% over placebo).

   “the percentage of parabasal cells decreased by 27.7% over placebo (P < 0.0001)”

   Human trial0.50% DHEAvagina6.5 mg12 weeksfemalesn = 325

   Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

   Menopause (New York, N.Y.)·Nov 1, 2018

2. Dehydroepiandrosterone decreases parabasal cells in humans (-45.8% compared with placebo (P < 0.0001)).

   “the percentage of parabasal cells decreased by 45.8% compared with placebo (P < 0.0001)”

   Human trial0.50%vagina6.5 mg12 weeksfemales

   Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)

   Menopause (New York, N.Y.)·Sep 1, 2015

3. Dehydroepiandrosterone decreases parabasal cells in humans (vaginal atrophy) (decreased by 42.4% to 54.9% vs placebo (p < 0.0001)).

   “increasing doses of 0.25%, 0.5% and 1.0% DHEA decreased the percentage of parabasal cells by 48.6 ± 6.78%, 42.4 ± 7.36% and 54.9 ± 6.60% (p < 0.0001 vs. placebo for all)”

   Human trialvaginal atrophyvagina12 weeksfemalesn = 114

   Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia

   Climacteric : the journal of the International Menopause Society·Jan 18, 2011

4. Dehydroepiandrosterone decreases parabasal cells in humans (vaginal atrophy).

   “percentage of parabasal cells and increased percentage of superficial cells”

   Human trialvaginal atrophyovulesvagina0.5%12 weeksfemales

   High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy

   Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·Jul 1, 2010

More on Dehydroepiandrosterone